Skip to main content
18/11/2026

Dr. Mar Tintoré is recognized on Clarivate’s Highly Cited Researchers 2026 list

Doctora Mar Tintoré

18/11/2026

For the fifth consecutive year, the contribution of Dr. Tintoré in the multiple sclerosis area is recognized.

Clarivate has revealed the annual list of Highly Cited Researchers 2026, curated by their experts at the Institute for Scientific Information (ISI). Of the world’s population of scientists and social scientists, Highly Cited Researchers are 1 in 1,000. This small fraction of the global researcher population contributes disproportionately to extending the frontiers of knowledge and contributing to innovations that make the world healthier, more sustainable and which drive societal impact.

Announced today, Clarivate has recognized 6,802 individuals with 7,090 awards from more than 1,200 institutions in 62 countries and regions. The number of Highly Cited Researcher designations exceeds the number of unique individuals who demonstrate significant and broad influence in their fields of research because some researchers are recognized in more than one Essential Science Indicators (ESI) field of research.

Each researcher selected has authored a minimum number of Highly Cited Papers (research documents which rank in the top 1% by citations for their field(s) and publication year in the Web of Science Core Collection over the past eleven years, 2015 - 2025) and has a minimum number of citations.

Neuroscience and Behaviour category

In the Neuroscience and Behaviour category, the list recognizes, for the fifth consecutive year, the contribution of Dr. Mar Tintoré, Head of Section in the Neurology Department at Vall d’Hebron University Hospital, Director of the Catalonia Multiple Sclerosis Centre (Cemcat), and Principal Investigator of the Clinical Neuroimmunology Group at the Vall d’Hebron Research Institute (VHIR).

Dr. Tintoré emphasized that “this recognition is, above all, the result of a collective effort. It reflects the work, talent and commitment of the entire Cemcat team, as well as the healthcare professionals and researchers who, day after day, work together to advance knowledge of multiple sclerosis and improve care for people living with the disease.” “I would also like to express my deepest gratitude to our patients and their families for the trust they place in us and for the generosity with which they participate in research projects. Without them, many of the advances achieved would not have been possible,” she added.

Dr. Xavier Montalban, who until early 2026 served as Director of Cemcat, Head of the Neurology Department at Vall d’Hebron University Hospital, and Head of the Clinical Neuroimmunology Group at VHIR, has also been recognized as a Highly Cited Researcher this year in the Neuroscience and Behaviour category.

To access Clarivate’s list Highly Cited Researchers 2026, click here.

Related news

A study conducted at the Catalan Multiple Sclerosis Centre (Cemcat) shows that the lack of a reduction in neurofilament light chain during the first year of treatment is associated with a higher risk of subsequent disease activity.

The project’s 4th annual meeting was recently held as part of the Fortalece–Salud programme of the Carlos III Health Institute.

An international study led by researchers from Vall d’Hebron shows that simple tests that patients can perform themselves help detect changes in disability that may occur even in the absence of disease relapses.

Related professionals

Mar Tintore Subirana

Mar Tintore Subirana

Main researcher
Clinical Neuroimmunology
Read more
Carlos Nos Llopis

Carlos Nos Llopis

Research technician
Clinical Neuroimmunology
Read more
Nuria Martínez Sabaté

Nuria Martínez Sabaté

Administration and Management
Clinical Neuroimmunology
Read more
Dunia Muñoz Valdivielso

Dunia Muñoz Valdivielso

Administration and Management
Clinical Neuroimmunology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.